New HCV Combination Treatment for Only $300 in Lower-Income Countries
Non-Profit’s $300 Hepatitis C Cure Rivals Current $48,000-Plus Options
An international medical non-profit organization has teamed up with an Egyptian drug manufacturer to develop a hepatitis C combination treatment that boasts cure rates comparable to the leading market pharmaceuticals – at less than 1 percent of the price.
Drugs for Neglected Diseases initiative (DNDi) released a statement on results from a clinical trial assessing the efficacy of ravidasvir – a new antiviral – taken with sofosbuvir, an existing medication. Set to be presented today at the International Liver Conference in Paris prior to publication in a journal, the dataset showed that a 12-week course of daily ravidasvir/sofosbuvir treatment completely eradicated traces of the virus from 97 percent of the study’s 301 patients, including those with the most severe forms of infection.
Continue reading this entire article: